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ABSTRACT
The insulin-like growth factor (IGF) system is an important reg-
ulator of fetal growth and differentiation. IGF bioavailability is mod-
ulated by IGF binding proteins (IGFBPs). We have generated six
different antisera, directed to synthetic peptide fragments of mouse
IGFBP-1 through -6. The specificity of the produced antisera was
demonstrated by enzyme-linked immunosorbent assay, Western blot-
ting, and by immunohistochemistry on sections of mouse embryos of
13.5 days post coitum. Specificity for the IGFBP-2 through -6 antisera
also was confirmed immunohistochemically in liver and lung of cor-
responding gene deletion (knock-out) mutant mice and wild-type lit-
ter mates.
Immunohistochemistry and messenger RNA (mRNA) in situ hy-
bridization on sections of mouse embryos of 13.5 days post coitum
revealed tissue-specific expression patterns for the six IGFBPs. The
only site of IGFBP-1 protein and mRNA production was the liver.
IGFBP-2, -4, and -5 protein and mRNA were detected in various
organs and tissues. IGFBP-3 and -6 protein and mRNA levels were
low. In several tissues, such as lung, liver, kidney, and tongue, more
than one IGFBP (protein and mRNA) could be detected. Differences
between mRNA and protein localization were extensive for IGFBP-3,
-5, and -6, suggesting that these IGFBPs are secreted and
transported.
These results confirm the different spatial localization of the
IGFBPs, on the mRNA and protein level. The overlapping mRNA and
protein localization for IGFBP-2 and -4, on the other hand, may
indicate that these IGFBPs also function in an auto- or paracrine
manner. (Endocrinology 140: 5944–5952, 1999)
THE INSULIN-LIKE growth factor (IGF) binding proteins(IGFBPs) are a family of at least six highly homologous
proteins that bind IGF with high affinity (1). Together with the
IGF receptors, IGFs and IGFBPs form the IGF system that is
important during development, where IGFBPs serve as regu-
lators of IGF bioavailability (2–5). Human fetal tissues synthe-
size and secrete IGFBPs in a tissue-specific fashion (6–9).
Mouse models are widely used to obtain insight into the
actions of the IGF system members during development
(10–14). Gene expression studies have shown that the IGF
system components have specific spatial and temporal mes-
senger RNA (mRNA) expression patterns during develop-
ment (15–20). Because the IGFs and IGFBPs are secreted
proteins, it is relevant to extend analysis of gene transcription
to the localization of the proteins at their site of action.
Several studies have confirmed the tissue-specific protein
localization of the components of the IGF system in the
human (7–9). The existing antibodies to rat IGFBPs, however,
are not applicable in immunohistochemical detection in mice
(21).
Therefore, the aim of this study was to generate specific
antisera against the mouse IGFBPs (mIGFBPs) and to com-
pare IGFBP protein localization patterns with IGFBP mRNA
patterns during mouse development. Specific mIGFBP an-
tisera were raised using synthetic peptides specific for each
of the IGFBPs and were characterized by enzyme-linked
immunosorbent assay (ELISA), Western blotting, and im-
munohistochemistry. Immunohistochemistry and in situ hy-
bridization were performed on sections of 13.5-dpc (days
post coitum) mouse embryos to analyze protein and mRNA
localization of the six IGFBPs.
Materials and Methods
Generation of antisera
Antisera to mIGFBP-1, -2, -3, -4, -5, and -6 were generated using
synthetic peptides (ID-DLO, Lelystad, The Netherlands) (Table 1). These
peptides were chosen from the unique middle part of the IGFBP amino
acid sequences, to limit cross-reactivity between the various IGFBPs. The
choice of the peptide fragments was guided by hydrophobicity plots
(22), surface probability predictions according to Emini, Chou-Fasman
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secondary structure predictions (23), and antigenicity index (24). A
terminal cystein was added to the peptide for sulfhydryl coupling.
Conjugation to the carrier keyhole limpet hemocyanin (KLH) was per-
formed, following the manufacturer’s prescription (Pierce Chemical Co.,
Rockford, IL). KLH-coupled peptides were injected sc into rabbits (0.25
mg), using specol (Central Veterinary Institute, Lelystad, the Nether-
lands) as adjuvant. Three weeks after primary immunization, the rabbits
were boosted (protocol similar to primary immunization). After a final
boost, 3 weeks later (similar to previous boost), sera were collected and
used in subsequent experiments.
ELISA
A total of 96 microwell plates were coated with peptide (without
KLH), 2 mg/ml in coupling buffer (50 mm carbonate buffer, pH 9.0), and
dried overnight at 37 C. After blocking with 3% BSA (fraction V; Roche
Molecular Biochemicals GmbH, Mannheim, Germany) in PBS dilution
gradients of the antisera were pipetted into the wells (1:500 to 1:16,000),
which were incubated overnight at 4 C. A peroxidase-conjugated swine
antirabbit antibody (DAKO Corp., Glostrup, Denmark) was used as a
secondary step (dilution 1:1,000) during 1 h. Detection was done with
o-phenyl diamine (Eastman Kodak Co., Rochester, NY) (20 mg o-phenyl
diamine 1 50 ml H2O2/10 ml 0.1 m citric acid, 0.2 m Na2HPO4, pH 5.0).
The reaction was stopped with 5 m H2SO4.
Negative controls were included, consisting of incubation of the wells
plate, coated with peptides, with preimmune sera of the respective
antisera, in the same dilutions. Cross-reactivity was checked by incu-
bating each peptide with all IGFBP antisera (dilutions 1:500 and 1:1,000).
Western blotting
Murine erythroleukemia (MEL) cells were transfected with IGFBP-1,
2, 4, and 6 complementary DNAs (17), according to Needham and
co-workers (25). In the log phase, these cells were induced for 48 h with
dimethylsulfoxide. Subsequently, cell culture medium was trichloric
acid precipitated (50 vol/vol 20%trichloric acid, overnight at 4 C) (Merck
KGaA, Darmstadt, Germany). IGFBP production was tested by IGF-
ligand blotting, as described by Hossenlopp et al. (26).
For IGFBP-3, normal mouse serum was used; whereas for IGFBP-5,
total protein was extracted from fetal mouse lungs (13.5 dpc) by the
TRIzol method, following the manufacturer’s prescription (Life Tech-
nologies, Rockville, MD).
Proteins were separated on a reducing 8% or 10% SDS:PAGE and
transferred either to polyvinylidene difluoride (PVDF) (Millipore Corp.,
Bedford, MA) or nitrocellulose (Schleicher & Schuell, Inc., Dassel, Ger-
many) membranes. The PVDF membranes were blocked with 5% nonfat
dry milk (Profilar, Nutricia, Zoetermeer, the Netherlands), the nitrocel-
lulose membranes with 3% BSA (Roche Molecular Biochemicals GmbH).
Membranes were incubated overnight at 4 C with the primary antibody
(dilutions varying from 1:200 to 1:20,000). As a secondary step, a per-
oxidase-conjugated swine antirabbit antibody was used (DAKO Corp.,
A/S; 1:2,000) on the PVDF membranes, 1 h at room temperature. The
nitrocellulose membranes were incubated with a secondary alkaline
phosphatase antibody (DAKO Corp., A/S). PVDF membranes were
incubated according to the manufacturer’s procedure (Pierce Chemical
Co.) and subsequently covered with ECL hyperfilms (Amersham Phar-
macia Biotech, Buckinghamshire, UK). Films were illuminated varying
from 1 min to 2 h, depending on the intensity of the signal. Detection
on nitrocellulose membranes took place with NBT (4-nitroblue tetrazo-
lium chloride) and BCIP (5-bromo-4-chloro-3-indolyl-phosphate).
Immunohistochemistry on sections
Balb/c mice were mated, and the morning of appearance of a vaginal
plug was assigned 0.5 dpc. Pregnant females were killed by cervical
dislocation, and embryos were collected at 13.5 dpc and fixed overnight
in 4% paraformaldehyde. Similarly, liver and kidneys from adult gene
deletion (knock-out) IGFBP-2 through -6 mutants (27–30) and their wild-
type litter mates were fixed overnight in 4% paraformaldehyde. After
embedding of the fixed tissues in paraffin, 5-mm sections were cut and
mounted onto aminopropyl trioxysilane-coated slides. Immunohisto-
chemistry was performed, making use of a peroxidase-antiperoxidase
(PAP) method or an avidine-biotine complex method. The anti-mIGFBP
antisera were used in a dilution of 1:250. Unlabeled goat antirabbit Igs
(dilution 1:50) (DAKO Corp.) were used as second antibody and rabbit
PAP (dilution 1:100) (DAKO Corp.) as a linker in the PAP method.
Incubation with a biotin-conjugated goat antirabbit (DAKO Corp.), com-
pleted with a streptavidin horseradish peroxidase complex (BioGenex
Laboratories, Inc., San Ramon, CA) incubation, was used for the avidine-
biotine complex method. Staining was performed with diaminobenzi-
dine (0.75 mg/ml) (DAB, Fluka Chemical Co., Buchs, Switzerland).
Nuclei were visualized with Mayer’s hematoxilin. The tissues were
analyzed under light microscopy. Controls were performed on sections
with preimmune sera of each rabbit, diluted 1:10 to 1:50. As a second
control, the immune sera were mixed in a dilution range with the
corresponding peptides (1, 0.5, and 0.17 mg/ml) and incubated overnight
at 4 C. With these mixtures, immunohistochemistry on sections of mouse
embryos was performed.
Probe preparation (in situ hybridization)
Specific mIGFBP complementary RNA probes were transcribed from
IGFBP-2, -3, -4, -5, and -6, as described by Schuller et al. (17). The mouse
complementary DNA SphI-SacI fragment was used as template for the
IGFBP-1 complementary RNA probe and was cloned into pTZ18R or
pTZ19R (Amersham Pharmacia Biotech, Uppsala, Sweden) for the an-
tisense and sense probes, respectively. Digoxigenin-11-UTP-labeled
RNA probes were prepared according to the manufacturer’s prescrip-
tion (Roche Molecular Biochemicals GmbH) using T7 or SP6 RNA
polymerase.
In situ hybridization
A nonradioactive in situ hybridization was performed, essentially as
described before (16). Hybridization was performed overnight at 55 C
in a humid chamber in a hybridization solution containing 50% deion-
ized formamide, 10% dextran sulfate, 2 3 SSC, 1 3 Denhardt’s solution,
1 mg/ml transfer RNA, 250 mg/ml herring sperm DNA, and the re-
spective probes at a concentration of 100 ng/ml. After various washes
(50% formamide/2 3 SSC, 50% formamide/1 3 SSC, and 0.1 3 SSC)
sections were incubated with ribonuclease T1 (2 U/ml in 1 mm EDTA/
2 3 SSC) for 15 min at 37 C. The digoxigenin-labeled hybrids were
detected by antibody incubation performed according to the manufac-
turer’s recommendations (Roche Molecular Biochemicals GmbH). PVA
(Polyvinylalcohol; molecular mass, 31–50 kDa; Aldrich, Milwaukee,
WI)-enhanced staining with BCIP, NBT, and levamisol was stopped
when the desired intensity of the blue precipitate was reached. This was
dependent on the relative abundance of the respective mRNAs. Sections
were counterstained with Nuclear red solution and mounted with Eu-
paral (ChromaGesellschaft, Stuttgart, Germany). Negative controls for
in situ hybridization were performed using sense probes, which never
gave any significant staining.
Results
Analysis of antisera specificity and cross-reactivity
After immunization and boost, all rabbits developed an-
tisera against the predicted mIGFBP. ELISA assay of the
antisera demonstrated a specific response to the injected
peptides (results not shown). Antisera against mIGFBP-1, -3,
-4, and -6 were very specific and already demonstrated a
clear color reaction at a dilution to 1:8,000. Clear color reac-
tion of antisera against IGFBP-2 and -5 were obtained at a
TABLE 1. Amino acid sequences of the synthetic peptide
fragments of the IGFBPs used to produce anti-mIGFBP antisera
IGFBP-1 174MRAREIADLKKWKEPC189
IGFBP-2 173CEKVNEQHRQMGKGAKH189
IGFBP-3 200FSSESKRETEYGPC213
IGFBP-4 155VGTPREEPRPVPQGSC170
IGFBP-5 177VIPAPEMRQESEQGPC192
IGFBP-6 127CSRDTNHRDRQKNPRTS143
The amino acid numbering of the corresponding IGFBP fragment
are given above.
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FIGS. 1–3. FIG. 1. Western immunoblots of mIGFBP-1, -3, and -5. mIGFBP-1: 100 mg IGFBP-1 containing culture supernatant from MEL cells
(ECL); dilution of the mIGFBP-1 antiserum, 1:20,000. IGFBP-3: 1 ml normal mouse serum (ECL); dilution of the mIGFBP-3 antiserum, 1:10,000.
IGFBP-5: total protein (80 mg) of 13.5-dpc mouse lungs (NBT/BCIP staining), dilution of the mIGFBP-5 antiserum, 1:1,000. FIG. 2. IGFBP-1
immunohistochemistry on the liver of a 13.5-dpc mouse embryo. a, Antiserum against IGFBP-1 (1:250) was blocked with 60 ng of the
corresponding IGFBP-1 per slide; b, IGFBP-1 (antiserum against IGFBP-1, 1:250; arrows, weak immunohistochemical staining of IGFBP-1);
c, IGFBP-1 mRNA (blue) by in-situ hybridization. FIG. 3. Immunohistochemical detection of IGFBP-2 protein (brown) and IGFBP-2 mRNA (blue)
in mouse adult kidney (a–c) and in embryonic (13.5-dpc) choroid plexus (d–f) and lung (g and h). a, Kidney, preimmune serum (1:20) as a control
for background staining; b, kidney, IGFBP-2 protein (arrow, IGFBP-2 protein in proximal tubules); c, kidney obtained from an IGFBP-2 gene
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dilution of 1:4,000. As a control, incubation with each of the
preimmune sera in a dilution range was included that
showed no significant staining. No cross-reactivity between
the antisera and the synthetic nonhomologous IGFBP pep-
tide fragments was observed (data not shown).
Detection of mIGFBPs on Western blot was possible for
mIGFBP-1, -3, and -5 (Fig. 1). The patterns on Western blot
corresponded with the IGF-ligand blot results (data not
shown). A distinct band of approximately 30 kDa was visible
for mIGFBP-1, after dilution of the antiserum to 1:20,000.
When 1 ml mouse serum was loaded, the IGFBP-3 43–45 kDa
doublet was visible after incubation with the anti-IGFBP-3
antiserum (diluted 1:10,000). Loading of total protein of 13.5-
dpc mouse lungs gave a band of approximately 29 kDa when
incubated with the IGFBP-5 antiserum (1:1,000). Neither of
the antisera demonstrated cross-reactivity to the other
IGFBPs.
Specificity of immunohistochemical detection of IGFBPs in
mouse tissues
Specificity of the generated mIGFBP antisera in immuno-
histochemistry was checked by incubating the antisera over-
night with the corresponding synthetic peptides in a dilution
range (60–10 ng/ml). Subsequently, these mixtures were
used in an immunohistochemical procedure on sections of
13.5-dpc mouse embryos. This resulted in a gradual loss of
signal with increasing peptide concentrations. An example is
given in Fig. 2. The loss of signal did not occur when non-
homologous peptides were used (data not shown).
Furthermore, for the antisera directed against mIGFBP-2
through -6, specificity was determined, using immunohis-
tochemistry on sections of liver and kidney from wild-type
animals, using preimmune serum as a control for back-
ground staining (see panels a in Figs. 3–7), on liver and
kidney from adult wild-type animals using the antiserum
(see panels b in Figs. 3–7), and on livers and kidneys from
adult gene deletion (knock-out) mutants with their respec-
tive antisera as a negative control (see panels c in Figs. 3–7).
IGFBP-2 preimmune serum resulted in a uniform back-
ground staining of renal structures including the tubules
(Fig. 3a). The mIGFBP-2 antiserum revealed a prominent
staining of the renal proximal tubules (Fig. 3b) that was
absent in IGFBP-2 gene deletion mutants (Fig. 3c).
IGFBP-3 preimmune serum resulted in a weak, uniform
hepatic staining (Fig. 4a). The mIGFBP-3 antiserum promi-
nently stained the endothelium of the veins and arteries
(Fig. 4b) that was absent in IGFBP-3 gene deletion mutants
(Fig. 4c).
IGFBP-4 preimmune serum revealed a weak uniform he-
patic staining (Fig. 5a). The mIGFBP-4 antiserum staining
was located around hepatic veins (Fig. 5b) and was absent in
IGFBP-4 gene deletion mutants (Fig. 5c).
IGFBP-5 preimmune serum resulted in a moderate stain-
ing of all renal tubules (Fig. 6a), whereas the mIGFBP-5
antiserum demonstrated a strong staining of the renal prox-
imal tubules superimposed on the background staining (Fig.
6b). This was in contrast to the IGFBP-5 gene deletion mu-
tants that only demonstrated a weak general renal staining
(Fig. 6c).
IGFBP-6 preimmune serum resulted in a moderate stain-
ing of all renal structures including the tubules (Fig. 7a). The
mIGFBP-6 antiserum demonstrated a strong staining of those
renal proximal tubules that were located in the proximity of
a blood vessel (Fig. 7b). This staining was absent in kidney
obtained from IGFBP-6 gene deletion mutants (Fig. 7c).
Comparison of protein and mRNA localization of the six
IGFBPs in the 13.5-dpc mouse embryo
The antisera against mIGFBP-1 through -6 were applied to
paraffin sections of mouse embryos (13.5 dpc) to localize
mIGFBP proteins. Similarly, mRNA expression patterns in
13.5-dpc mouse embryos were determined by in situ hybrid-
ization. In situ hybridization and immunohistochemistry
staining patterns are summarized in Table 2.
IGFBP-1 gene expression was limited. Staining of IGFBP-1
protein was visualized only in the liver, similar to IGFBP-1
mRNA expression (Fig. 2, b and c).
Like IGFBP-2 mRNA expression, IGFBP-2 protein occur-
rence was diverse. Major sites of IGFBP-2 protein localization
were liver, kidney, choroid plexus, lung, and floor plate. This
is in accordance with mRNA expression. Both IGFBP-2
mRNA and protein were located in the epithelial cells of the
kidney and choroid plexus (Fig. 3, d–f). In lung, IGFBP-2
mRNA and protein were present in the tubule, but also
scattered in underlying mesenchymal cells (Fig. 3, g and h).
However, there was a discrepancy between the tubular lo-
calization of IGFBP-2 mRNA and protein. The mRNA was
located in the epithelial cells, whereas IGFBP-2 protein was
detected in the underlying tubular cells.
IGFBP-3 mRNA expression was weak and colocalized
with IGFBP-3 protein in liver, tongue, lung and in nose
epithelium (very weak signal) (Fig. 4, d–g). In the tongue,
IGFBP-3 mRNA and protein were not colocalizing but ex-
pressed in neighboring cell types in muscle (Fig. 4, f and g).
In contrast to mRNA expression, IGFBP-3 protein also could
be detected in the choroid plexus and kidney, whereas
mRNA expression could also be detected in the heart.
In accordance with its mRNA expression, staining of
IGFBP-4 protein was detected widespread. Overlapping
mRNA and protein expression was visualized in mesen-
cephalon, telencephalon (Fig. 5, d and e), heart, liver, lung,
tongue mesenchyme, and blood vessels. In addition to the
mRNA expression profiles, IGFBP-4 protein could be dem-
onstrated in the kidney (results not shown).
IGFBP-5 mRNA was expressed abundantly and was
largely overlapping protein occurrence. Identical to mRNA
expression, IGFBP-5 protein was localized in the liver, en-
dothelium of the gut, meninges, tubules and mesenchyme of
the lung (very weak protein staining) (Fig. 6, d–g), and
deletion (K.O.) mutant, control for the specificity of the IGFBP-2 antiserum; d, choroid plexus, preimmune serum as a negative control for
IGFBP-2 (1:20); e, IGFBP-2 protein in the choroid plexus (arrows, IGFBP-2 protein in epithelial cells); f, IGFBP-2 mRNA in the choroid plexus;
g, IGFBP-2 protein in lung (arrow, IGFBP-2 protein in tubular cells; arrowhead, IGFBP-2 protein in mesenchymal cells); h, IGFBP-2 mRNA
in lung (arrow, localization in epithelial cells; arrowhead, localization in mesenchymal cells).
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FIGS. 4–5. FIG. 4. Immunohistochemical detection of IGFBP-3 protein (brown) and IGFBP-3 mRNA (blue) in mouse adult liver (a–c) and in
embryonic (13.5-dpc) liver (d and e) and tongue (f and g). a, Liver, serum (1:20) as a control for background staining; b, liver, IGFBP-3 protein
(arrow, IGFBP-3 protein in venous endothelium; arrowhead, IGFBP-3 protein in a hepatic artery; c, liver obtained from an IGFBP-3 gene deletion
(K.O.) mutant, control for the specificity of the IGFBP-3 antiserum; d, IGFBP-3 protein in liver; e, IGFBP-3 mRNA in liver; f, IGFBP-3 protein
in tongue (muscle); g, IGFBP-3 mRNA (arrow) neighbors IGFBP-3 protein in tongue. FIG. 5. Immunohistochemical detection of IGFBP-4 protein
(brown) and IGFBP-4 mRNA (blue) in mouse adult liver (a–c) and in 13.5-dpc embryonic hindbrain (d and e). a, Liver, preimmune serum (1:20)
as a control for background staining; b, IGFBP-4 protein (arrow, IGFBP-4 protein in cells surrounding a hepatic vein); c, liver obtained from
an IGFBP-4 gene deletion (K.O.) mutant, control for the specificity of the IGFBP-4 antiserum; d, IGFBP-4 protein in hindbrain; e, IGFBP-4
mRNA (arrow) in hindbrain.
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FIGS. 6–7. FIG. 6. Immunohistochemical detection of IGFBP-5 protein (brown) and IGFBP-5 mRNA (blue) in mouse adult kidney (a–c) and in
13.5-dpc embryonic lung (d and e) and 19.5-dpc embryonic lung (f and g). a, Kidney, preimmune serum (1:20) as a control for background staining;
b, kidney, IGFBP-5 protein (arrow, IGFBP-5 protein in proximal tubules); c. kidney obtained from an IGFBP-5 gene deletion (K.O.) mutant,
control for the specificity of the IGFBP-5 antiserum; d, IGFBP-5 protein in 13.5-dpc lung; e, IGFBP-5 mRNA in 13.5-dpc lung; f, IGFBP-5 protein
in 19.5-dpc lung; g, IGFBP-5 mRNA in 19.5-dpc lung. FIG. 7. Immunohistochemical detection of IGFBP-6 protein (brown) and IGFBP-6 mRNA
(blue) in mouse adult kidney (a–c) and in 13.5-dpc embryonic nasal epithelium (d) and liver (e). a, Kidney, preimmune serum (1:20) as a control
for background staining; b, kidney, IGFBP-6 protein (arrow; IGFBP-6 protein in proximal tubules located around a vein); c, kidney obtained
from an IGFBP-6 gene deletion (K.O.) mutant, control for the specificity of the IGFBP-6 antiserum; d, IGFBP-6 protein in the nasal epithelium;
e, IGFBP-6 mRNA in liver.
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tongue. In addition, protein was detected in the notochord,
the floor plate, and muscle.
Colocalization of IGFBP-6 protein (Fig. 7d) and mRNA
(weak, result not shown) was observed in nasal epithelium
and in the liver (Fig. 7e). Protein was not detected in the
perichondral layer of cartilage, as was found for mRNA. In
addition, IGFBP-6 protein was visualized in hindbrain and
the heart (results not shown).
Discussion
To analyze IGFBP protein localization in mouse embryo-
nal tissues, we generated specific antisera against mIGFBP-1
through-6. The specificity of these antisera was demon-
strated by ELISA, Western blotting (for IGFBP-1, -3, and -5),
and immunohistochemistry on wild-type and IGFBP gene
deletion mutants.
All antisera demonstrated specific staining patterns that
were absent in preimmune controls and in tissues obtained
from the corresponding gene deletion mutant. The fact that
the antisera against mIGFBP-2, -4, and -6 were not able to
detect the corresponding IGFBP on Western blot may be
attributable to conformational changes of the protein in-
duced by the Western-blot procedure.
Furthermore, immunohistochemical localization of
mIGFBP proteins (mIGFBP-1 to -6) was compared with the
mRNA patterns obtained with in situ hybridization of sec-
tions of the midgestational mouse embryo. These data extend
our former gene expression studies that describe the tissue-
specific mRNA expression of IGFBP-1 through -6 in the
mouse embryo (15–17, 31, 32) and will be discussed.
Our results show that, similar to mRNA expression pat-
terns, localization of IGFBP proteins in the mouse midges-
tational embryo is tissue-specific. IGFBP-1 mRNA and pro-
tein were detected primarily in the liver, whereas IGFBP-2,
-4, and -5 were distributed among various tissues. Conform
the low IGFBP-1, -3, and -6 mRNA levels, these IGFBPs were
more difficult to detect than the other IGFBPs.
The limited data available on IGF system mRNA and pro-
tein expression during human development confirm our
data (7–9, 33). IGFBP-2 expression is prominent during de-
velopment of the nervous system, and the abundant IGFBP-2
protein and mRNA expression we observed in the choroid
plexus confirmed previous observations (34, 35). In this re-
spect, it is striking to note that we often observed a nuclear
IGFBP-2 immunoreactivity in the embryological tissues. Al-
though it is tempting to speculate about an intranuclear
IGFBP-2 localization, such as described for IGFBP-3 (36), this
cannot be concluded from these experiments.
Although protein localization of the IGFBPs seemed to be
mostly similar to mRNA expression, some differences in
localization in the 13.5-dpc mouse embryo were dem-
onstrated.
Differences between IGFBP mRNA and protein localiza-
tion may reveal detection thresholds for either mRNA or
protein, or secretion of the protein without binding to the
target organ (and protein is then probably washed out during
the immunohistochemical procedure). Discrepancy between
protein and mRNA expression was seen within tissues. In
lung, IGFBP-2 mRNA was detected in epithelial cells of the
tubules. However, IGFBP-2 protein was localized in the
neighboring tubular cells. Similarly, IGFBP-3 mRNA and
protein were located in neighboring cells in muscles of the
tongue. Apparently, in these cases, mRNA expression in a
given cell-type gives rise to protein localization in a cell-type
that is in close contact. This may point to a mechanism of
action where a certain cell type makes and secretes an IGFBP
that acts at another (neighboring) cell-type.
Furthermore, substantial differences between mRNA and
protein localization were found for IGFBP-3, -5, and -6.
IGFBP-3 is the major circulatory IGFBP (1); and, after its
TABLE 2. Localization of protein and mRNA of IGFBP-1 through -6 in major organs and tissues of the 13.5-dpc mouse embryo
Protein mRNA Protein mRNA
IGFBP-1 Liver Liver IGFBP-4 Mesencephalon Mesencephalon
Telencephalon Telencephalon
IGFBP-2 Lung Lung Heart Heart
Liver Liver Liver Liver
Kidney Kidney Lung Lung
Choroid plexus Choroid plexus Tongue Tongue
Floor plate Floor plate Bloodvessels Bloodvessels
Kidney
IGFBP-3 Liver Liver
Tongue Tongue IGFBP-5 Liver Liver
Lung Lung Gut endothelium Gut endothelium
Nasal epithelium Nasal epithelium Meninges Meninges
Heart Lung mesenchyme Lung mesenchyme
Choroid plexus Tongue Tongue
Kidney Notochord
Floor plate
Muscle
IGFBP-6 Liver Liver
Nasal epithelium Nasal epithelium
Perichondral
Layers of cartilage
Hindbrain
Heart
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secretion in liver and the cardiovasculair system, IGFBP-3
can easily move throughout the embryo. The IGFBPs may be
transported to specific sites, but the differences also may
indicate that the mRNA is very labile in these specific tissues
and, hence, present in concentrations below detection limits.
In that case, translation should be efficient, and the protein
must be very stable to enable protein detection.
Whereas mRNA and protein expression of the different
IGFBPs was clearly distinct, most tissues were found to ex-
press more than one IGFBP. Examples are liver, lung, heart,
and tongue. Two possible explanations for this phenomenon
exist: all IGFBPs have a specific function and each contribu-
tion is necessary for a functional organ; or all IGFBPs have
similar functions and show redundancy.
The fact that IGFBP knock-outs do not show dramatic
phenotypes (14, 37) may suggest overlapping function or
redundancy. The IGFBP-2 knock-outs are characterized by
an decreased spleen size and changed IGFBP serum levels,
probably to compensate for the lack of IGFBP-2 (37). The
body weight and body length of the IGFBP-4 knock-outs are
slightly smaller than of wild-type mice (14). However, these
minor changes seen cannot be explained by changed patterns
of IGFBP expression in tissues of interest.
The tissue-specificity of the IGFBPs and the consistence
between IGFBP mRNA and protein localization patterns may
suggest that the IGFBPs (except IGFBP-3) function in an
autocrine or paracrine manner. The fact that several tissues
express more than one IGFBP can also be explained as an
indication for the complex regulation of the IGF system.
Summarizing, the generated antisera against mIGFBP-1
through -6 demonstrated specificity in ELISA, Western-blot,
and immunohistochemistry. With these antisera, IGFBP pro-
tein localization could be compared with IGFBP mRNA ex-
pression patterns in 13.5-dpc mouse embryos. This revealed
tissue-specific and consistent mRNA and protein localiza-
tion, in confirmation with the suggested para- and autocrine
functions of the IGFBPs on IGF action.
We anticipate that this set of specific antisera may become
an important tool for future studies of IGFBP studies in the
mouse.
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